Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Austar LifesciencesAULSF 45 EV-to-EBIT is 7.79 as of Aug. 22, 2026, which is 8% below its 10-year median of 8.50. GuruFocus rates AULSF with a GF Score™ of 45/100 and a GF Value™ of $0.08 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 473 Medical Devices & Instruments companies, Austar Lifesciences ranks better than 84.14% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Austar Lifesciences's Enterprise Value for the quarter that ended in Dec. 2025 was $52.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Austar Lifesciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $8.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Austar Lifesciences EV-to-EBIT Related Terms
Austar Lifesciences EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Austar Lifesciences's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Austar Lifesciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Austar Lifesciences EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Austar Lifesciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Austar Lifesciences's EV-to-EBIT falls into.
Austar Lifesciences's current Enterprise Value is $65.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Austar Lifesciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $8.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Austar Lifesciences (AULSF) has a EV-to-EBIT of 7.79 as of Aug. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Austar Lifesciences and its competitors. This is near median its historical median of 8.50. According to the industry distribution chart, Austar Lifesciences ranks #75 out of 473 companies in the Medical Devices & Instruments industry, placing it in the top 15.9%.
Is Austar Lifesciences' EV-to-EBIT too high?
Austar Lifesciences' current EV-to-EBIT of 7.79 is near median its 10-year median of 8.50. The Medical Devices & Instruments industry median EV-to-EBIT is 18.87. Austar Lifesciences' value of 7.79 is 58.7% below this industry median. Based on the distribution chart, Austar Lifesciences ranks #75 out of 473 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Austar Lifesciences has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Austar Lifesciences' EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Austar Lifesciences ranks #75 out of 473 companies for EV-to-EBIT. This places Austar Lifesciences in the top 16% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 18.87. Austar Lifesciences' value of 7.79 is 58.7% below this benchmark. While the company's 10-year median is 8.50 vs. the industry median of 18.87, Austar Lifesciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.87, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Austar Lifesciences's current EV-to-EBIT of 7.79 is 58.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Austar Lifesciences and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Austar Lifesciences's current EV-to-EBIT is 7.79, which is near median its own 10-year median of 8.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Austar Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Austar Lifesciences (AULSF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.08, compared to a current price of $0.02 — trading 75% below its estimated fair value. The current EV-to-EBIT is 7.79, which is near median its 10-year median of 8.50 and 58.7% below the Medical Devices & Instruments industry median of 18.87. Austar Lifesciences' overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Austar Lifesciences (AULSF), the current EV-to-EBIT is 7.79 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Austar Lifesciences (AULSF) Overvalued in 2026?
Based on GuruFocus' analysis, Austar Lifesciences stock appears to be undervalued.
The current stock price of $0.02 is trading 75% below its estimated GF Value™ of $0.08.
GuruFocus considers Austar Lifesciences to be Possible Value Trap.
Key valuation signals for AULSF:
EV-to-EBIT: 7.79 (near median its 10-year median of 8.50)
GF Value™: $0.08 vs. price of $0.02 (75% below fair value)
Industry Position: 58.7% below the Medical Devices & Instruments median (#75 of 473)
No single metric tells the full story. See the AULSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Austar Lifesciences Ltd is an investment holding company, and its subsidiaries are principally engaged in providing integrated engineering solutions to pharmaceutical manufacturers and research institutes, as well as manufacturing and distribution of pharmaceutical equipment and consumables in the PRC. Its products include Clean Utility Equipment & Chemical Pharmaceutical Preparation System and others. It has three business segment groups: Integrated Process and Packaging Equipment & Systems (IPS), which generates maximum revenue and combines the original business segments of Liquid and Bioprocess System and Powder and Solid System; Consulting, Digitalization, and Construction; and Life Science Equipment and Consumables. The Group generates maximum revenue from Mainland China.
45GF Score
Get the complete analysis for AULSF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AULSF has been successfully added to your 
